Your browser doesn't support javascript.
loading
Five-Year Survival Rate of Bladder Cancer in Iran during 2001-2007.
Khayamzadeh, Maryam; Aliakbari, Fereshte; Zolghadr, Zahra; Emadeddin, Majid; Ahadi, Mahsa; Akbari, MohammadEsmaeil; Abedi, Amir Reza; Nematollahi, Shahrzad; Hosseini, Jalil.
Afiliação
  • Khayamzadeh M; Cancer Research Centre, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
  • Aliakbari F; Men's Health and Reproductive Health Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
  • Zolghadr Z; Department of Biostatistics, School of Allied Medical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
  • Emadeddin M; Men's Health and Reproductive Health Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
  • Ahadi M; Men's Health and Reproductive Health Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
  • Akbari M; Cancer Research Centre, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
  • Abedi AR; Urology Department, Shohada-ye Tajrish Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
  • Nematollahi S; Men's Health and Reproductive Health Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
  • Hosseini J; Men's Health and Reproductive Health Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Iran J Pathol ; 16(1): 69-74, 2021.
Article em En | MEDLINE | ID: mdl-33391383
ABSTRACT
BACKGROUND &

OBJECTIVE:

Bladder cancer is the fourth most common cancer in men and the most common cancer in women, comprising 8% of all males and 3% of female tumors. The present study aimed to estimate the five-year survival rates of bladder cancer in Iran.

METHODS:

Information on 3,337 registered cases of bladder cancer was obtained from the Office of National Cancer Registry in the Ministry of Health and Medical Education (MOH & ME). A telephone survey was conducted to gather additional information, such as survival status, demographic, and clinical profile. Kaplan-Meier estimates of five-year survival rates were calculated according to the age of diagnosis, gender, pathological type, and provincial pole. RESULTS AND

CONCLUSION:

Overall five-year survival rate was 77%. According to the pathologic type, five-year survival rates were 81%, 66%, 81%, 42%, 77%, and 82% in low-grade urothelial carcinoma, high-grade urothelial carcinoma, adenocarcinoma, undifferentiated carcinomas, Squamous Cell Carcinomas (SCCs), and other tumors, respectively. Additionally, those tumors were 93%, 88%, 81%, 64%, and 44% among patients whose average ages at diagnosis were < 50, 50-59, 60-59, 70-79, and > 80 years old, respectively. Our study revealed that age and histological type were the major prognostic factors for survival in patients with bladder cancer. Therefore, given the histologic features of the tumor and patients with advanced age, a continuous screening would be highly warranted.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Ano de publicação: 2021 Tipo de documento: Article